Valuation: Theralase Technologies Inc.

Market Cap 78.35M 56.22M 48.63M 45.41M 41.66M 5.35B 79.6M 533M 209M 2.68B 211M 206M 8.87B P/E 2026 *
-26.5x
P/E 2027 * 13.3x
Enterprise Value 78.35M 56.22M 48.63M 45.41M 41.66M 5.35B 79.6M 533M 209M 2.68B 211M 206M 8.87B EV / Sales 2026 *
97.7x
EV / Sales 2027 * 2.31x
Free-Float
87.46%
Yield 2026 *
-
Yield 2027 * -
1 day+1.92%
1 week-7.02%
Current month-7.02%
1 month-1.85%
3 months-10.17%
6 months-14.52%
Current year+60.61%
1 week 0.26
Extreme 0.26
0.3
1 month 0.25
Extreme 0.25
0.3
Current year 0.16
Extreme 0.16
0.41
1 year 0.14
Extreme 0.145
0.41
3 years 0.14
Extreme 0.14
0.41
5 years 0.14
Extreme 0.14
0.48
10 years 0.12
Extreme 0.12
0.6
Manager TitleAgeSince
Chief Executive Officer - 28/06/2023
Director of Finance/CFO - 26/06/2019
Chief Executive Officer - 14/11/2021
Director TitleAgeSince
Chairman - -
Director/Board Member - 31/12/2007
Director/Board Member - 26/06/2019
Date Insider Type Main position Quantity % Market Cap.
20/05/26 Buy

Director

20,900 0.0081%
20/05/26 Option

Chief Financial Officer

11,000 0.0043%
31/07/25 Sell

Chief Financial Officer

130,000 0.0525%
Change 5-day change 1-year change 3-year change Capi.($)
+1.92%-7.02%+20.45%-5.36% 56.22M
+1.19%+3.73%+35.12%+58.51% 1.49B
+1.83%+5.71%-7.19%-48.73% 54.52M
Average +1.65%+0.81%+16.13%+1.47% 534.79M
Weighted average by Cap. +1.24%+3.42%+33.17%+52.62%

Financials

2026 *2027 *
Net sales 802K 575K 498K 465K 426K 54.76M 815K 5.45M 2.14M 27.45M 2.16M 2.11M 90.75M 33.89M 24.31M 21.03M 19.64M 18.02M 2.31B 34.43M 230M 90.44M 1.16B 91.3M 89.31M 3.83B
Net income -4.2M -3.01M -2.61M -2.43M -2.23M -287M -4.27M -28.56M -11.21M -144M -11.32M -11.07M -475M 6.83M 4.9M 4.24M 3.96M 3.63M 466M 6.94M 46.45M 18.23M 234M 18.4M 18M 773M
Net Debt - -
Logo Theralase Technologies Inc.
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
Employees
20
Date Price Change Volume
07/08/26 CA$0.2650 +1.92% 76,860
06/08/26 CA$0.2600 0.00% 17,000
05/08/26 CA$0.2600 -3.70% 65,703
04/08/26 CA$0.2700 -5.26% 141,513
31/07/26 CA$0.2850 +1.79% 152,151
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2650CAD
Average target price
0.7000CAD
Spread / Average Target
+164.15%

Quarterly revenue - Rate of surprise